Zenith Drugs Limited (NSE:ZENITHDRUG)

Market Cap	779.41M -44.5%
Revenue (ttm)	1.44B +10.0%
Net Income	37.77M -61.0%
EPS	2.20 +30.4%
Shares Out	17.15M
PE Ratio	20.66
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,400
Open	45.90
Previous Close	46.45
Day's Range	45.00 - 46.40
52-Week Range	33.30 - 82.95
Beta	1.41
Analysts	n/a
Price Target	n/a
Earnings Date	May 29, 2026

About Zenith Drugs

Zenith Drugs Limited, together with its subsidiaries, manufactures and trades in branded, generic, and OTC medicines. The company offers a range of pharmaceutical formulations, such as ORS powder, liquid orals, ointments, creams, gels, liquid externals, capsules, and tablets. Its products are indicated for allergology, general analytics, infections, genetics, endocrinology, and microbiology. The company operates in India, Costa Rica, Mauritius, Cambodia, Myanmar, Yemen, Sierra, Leone, Liberia, and Bhutan. Zenith Drugs Limited was incorporated i...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1956
• Employees: 182
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ZENITHDRUG

Financial Performance

In fiscal year 2025, Zenith Drugs's revenue was 1.33 billion, an increase of 1.29% compared to the previous year's 1.32 billion. Earnings were 71.61 million, a decrease of -24.92%.